Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-07-11
2006-07-11
Borin, Michael (Department: 1631)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600
Reexamination Certificate
active
07074764
ABSTRACT:
The present invention relates to a method and composition for treating a patient having a condition characterized as inflammatory bowel disease with an effective dose of HGF. Inflammatory bowel disease as defined by the present invention, includes Chronic Ulcerative Colitis, Crohn's Disease, necrotizing enterocolitis, severe acute gastroenteritis, chronic gastroenteritis, cholera, chronic infections of the bowel, immunologic disorders affecting the intestine, immunodeficiency syndromes affecting the intestine, and HIV. Mucosal damage and histologic lesions are reduced by administering an effective dose of HGF to patients suffering from the same. Specifically, the effective dose of HGF is in a range of about 30 μg/kg body weight/day to about 300 μg/kg body weight/day. HGF may be administered to the patient lumenally or systemically.
REFERENCES:
patent: 08231418 (1995-02-01), None
Zushi et al. Am. J. Physiol.270, G757-G762, 1996.
Fukamachi et al. Biochem. Biophys. Research Communication, 205 (2), 1445-1451.
Halttunen et al. Gastroenterology, 111, 1252-1262, 1996.
Bozkurt et al. J Clin Ultrasound. Feb. 1994;22(2):85-91; see abstract.
Nasrat et al. Journal of Clinical Investigation, 93(5), 2056-2065, 1994.
Dignass et al. Biochemical and Biophysical Research Communications, 202(2), 701-709, 1994.
“Importance of fibroblastic support for in vitro differentiation of intestinal endodermal cells and for their response to glucocorticoids,” by M. Kedinger, P. Simon-Assmann, E. Alexandre and K. Haffen,Cell Differentiation, 20 (1987) 171-182.
“Preliminary Cultures for Studies of Cell Regulation and Physiology in Intestinal Epithelium,” by G. S. Evans, N. Flint, and C. S. Potten,Annun. Rev. Physiol.,(1994) 56: 399-417.
“The development of a method for the preparation of rat intestinal epithelial cell primary cultures,” by G. S. Evans, N. Flint, A. S. Somers, B. Eyden and C. S. Potten,Journal of Cell Science, 101 (1992) 219-231.
“Iron Absorption; Characterization of isolated duodenal epithelial cells along a crypt-villus axis in rats fed diets with different iron content,” by Philip S. Oates, Carla Thomas and Evan H. Morgan,Journal of Gastroenterology and Hepatology(1997) 12; 829-838.
Borin Michael
McGuireWoods LLP
The Nemours Foundation
LandOfFree
Treatment of intestinal epithelial cell malfunction,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of intestinal epithelial cell malfunction,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of intestinal epithelial cell malfunction,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3587447